Literature DB >> 18723090

Ubiquitin, proteasomes and proteolytic mechanisms activated by kidney disease.

Vik Rajan1, William E Mitch.   

Abstract

The ubiquitin-proteasome system (UPS) includes 3 enzymes that conjugate ubiquitin to intracellular proteins that are then recognized and degraded in the proteasome. The process participates in the regulation of cell metabolism. In the kidney, the UPS regulates the turnover of transporters and signaling proteins and its activity is down regulated in acidosis-induced proximal tubular cell hypertrophy. In chronic kidney disease (CKD), muscle wasting occurs because complications of CKD including acidosis, insulin resistance, inflammation, and increased angiotensin II levels stimulate the UPS to degrade muscle proteins. This response also includes caspase-3 and calpains which act to cleave muscle proteins to provide substrates for the UPS. For example, caspase-3 degrades actomyosin, leaving a 14 kDa fragment of actin in muscle. The 14 kDa actin fragment is increased in muscle of patient with kidney disease, burn injury and surgery. In addition, acidosis, insulin resistance, inflammation and angiotensin II stimulate glucocorticoid production. Glucocorticoids are also required for the muscle wasting that occurs in CKD. Thus, the UPS is involved in regulating kidney function and participates in highly organized responses that degrade muscle protein in response to loss of kidney function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723090      PMCID: PMC2637460          DOI: 10.1016/j.bbadis.2008.07.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  61 in total

1.  Enac degradation in A6 cells by the ubiquitin-proteosome proteolytic pathway.

Authors:  B Malik; L Schlanger; O Al-Khalili; H F Bao; G Yue; S R Price; W E Mitch; D C Eaton
Journal:  J Biol Chem       Date:  2001-01-26       Impact factor: 5.157

2.  Malnutrition: a frequent misdiagnosis for hemodialysis patients.

Authors:  William E Mitch
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

3.  Expression of a calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse.

Authors:  James G Tidball; Melissa J Spencer
Journal:  J Physiol       Date:  2002-12-15       Impact factor: 5.182

Review 4.  Caspases: intracellular signaling by proteolysis.

Authors:  G S Salvesen; V M Dixit
Journal:  Cell       Date:  1997-11-14       Impact factor: 41.582

5.  National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure.

Authors:  J D Kopple
Journal:  Am J Kidney Dis       Date:  2001-01       Impact factor: 8.860

6.  Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo.

Authors:  S C Bodine; T N Stitt; M Gonzalez; W O Kline; G L Stover; R Bauerlein; E Zlotchenko; A Scrimgeour; J C Lawrence; D J Glass; G D Yancopoulos
Journal:  Nat Cell Biol       Date:  2001-11       Impact factor: 28.824

7.  Nutrition in CAPD: serum bicarbonate and the ubiquitin-proteasome system in muscle.

Authors:  Warren P Pickering; S Russ Price; Gemma Bircher; Anne C Marinovic; William E Mitch; John Walls
Journal:  Kidney Int       Date:  2002-04       Impact factor: 10.612

8.  Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I.

Authors:  M Brink; S R Price; J Chrast; J L Bailey; A Anwar; W E Mitch; P Delafontaine
Journal:  Endocrinology       Date:  2001-04       Impact factor: 4.736

9.  Identification of ubiquitin ligases required for skeletal muscle atrophy.

Authors:  S C Bodine; E Latres; S Baumhueter; V K Lai; L Nunez; B A Clarke; W T Poueymirou; F J Panaro; E Na; K Dharmarajan; Z Q Pan; D M Valenzuela; T M DeChiara; T N Stitt; G D Yancopoulos; D J Glass
Journal:  Science       Date:  2001-10-25       Impact factor: 47.728

10.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey.

Authors:  Josef Coresh; Brad C Astor; Tom Greene; Garabed Eknoyan; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2003-01       Impact factor: 8.860

View more
  18 in total

Review 1.  The role of the ubiquitin-proteasome system in kidney diseases.

Authors:  Hirotaka Fukasawa
Journal:  Clin Exp Nephrol       Date:  2012-06-09       Impact factor: 2.801

Review 2.  Current status of bicarbonate in CKD.

Authors:  Mirela Dobre; Mahboob Rahman; Thomas H Hostetter
Journal:  J Am Soc Nephrol       Date:  2014-08-22       Impact factor: 10.121

3.  Ubiquitin degradation with its substrate, or as a monomer in a ubiquitination-independent mode, provides clues to proteasome regulation.

Authors:  Nitzan Shabek; Yifat Herman-Bachinsky; Aaron Ciechanover
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-06       Impact factor: 11.205

Review 4.  Physiological functions and clinical implications of the N-end rule pathway.

Authors:  Yujiao Liu; Chao Liu; Wen Dong; Wei Li
Journal:  Front Med       Date:  2016-09-07       Impact factor: 4.592

Review 5.  Inflammation and cachexia in chronic kidney disease.

Authors:  Wai W Cheung; Kyung Hoon Paik; Robert H Mak
Journal:  Pediatr Nephrol       Date:  2010-01-29       Impact factor: 3.714

Review 6.  The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy.

Authors:  Victoria C Foletta; Lloyd J White; Amy E Larsen; Bertrand Léger; Aaron P Russell
Journal:  Pflugers Arch       Date:  2011-01-11       Impact factor: 3.657

7.  Combined treatment of carfilzomib and z-VAD-fmk inhibits skeletal proteolysis and apoptosis and ameliorates cancer cachexia.

Authors:  Qiang Wang; Chunhong Li; Xudong Peng; Qingjie Kang; Dawei Deng; Liuping Zhang; Yueyong Zheng; Chaoyi Wang; Zhongpeng Qiao; Dunwei Guo; Song You; Hua Tang
Journal:  Med Oncol       Date:  2015-03-04       Impact factor: 3.064

8.  Angiotensin II upregulates protein phosphatase 2Cα and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting.

Authors:  A Michael Tabony; Tadashi Yoshida; Sarah Galvez; Yusuke Higashi; Sergiy Sukhanov; Bysani Chandrasekar; William E Mitch; Patrice Delafontaine
Journal:  Hypertension       Date:  2011-08-15       Impact factor: 10.190

Review 9.  Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.

Authors:  Mark J Ranek; Xuejun Wang
Journal:  Curr Hypertens Rep       Date:  2009-12       Impact factor: 5.369

10.  Alterations in the ubiquitin proteasome system in persistent but not reversible proteinuric diseases.

Authors:  Maire Beeken; Maja T Lindenmeyer; Simone M Blattner; Victoria Radón; Jun Oh; Tobias N Meyer; Diana Hildebrand; Hartmut Schlüter; Anna T Reinicke; Jan-Hendrik Knop; Anuradha Vivekanandan-Giri; Silvia Münster; Marlies Sachs; Thorsten Wiech; Subramaniam Pennathur; Clemens D Cohen; Matthias Kretzler; Rolf A K Stahl; Catherine Meyer-Schwesinger
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.